- Home
- XPON vs THAR Comparison
XPON vs THAR Comparison
Compare XPON & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- THAR
- Stock Information
- Founded
- XPON 2016
- THAR 2017
- Country
- XPON United States
- THAR United States
- Employees
- XPON N/A
- THAR N/A
- Industry
- XPON Electronic Components
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- XPON Technology
- THAR Health Care
- Exchange
- XPON Nasdaq
- THAR Nasdaq
- Market Cap
- XPON 2.7M
- THAR 2.4M
- IPO Year
- XPON 2022
- THAR 2022
- Fundamental
- Price
- XPON $0.93
- THAR $1.36
- Analyst Decision
- XPON
- THAR Strong Buy
- Analyst Count
- XPON 0
- THAR 1
- Target Price
- XPON N/A
- THAR $17.00
- AVG Volume (30 Days)
- XPON 39.9K
- THAR 190.3K
- Earning Date
- XPON 05-13-2025
- THAR 05-08-2025
- Dividend Yield
- XPON N/A
- THAR N/A
- EPS Growth
- XPON N/A
- THAR N/A
- EPS
- XPON N/A
- THAR N/A
- Revenue
- XPON $5,624,939.00
- THAR N/A
- Revenue This Year
- XPON $61.26
- THAR N/A
- Revenue Next Year
- XPON N/A
- THAR N/A
- P/E Ratio
- XPON N/A
- THAR N/A
- Revenue Growth
- XPON N/A
- THAR N/A
- 52 Week Low
- XPON $0.67
- THAR $0.95
- 52 Week High
- XPON $236.00
- THAR $6.45
- Technical
- Relative Strength Index (RSI)
- XPON 51.83
- THAR 57.72
- Support Level
- XPON $0.74
- THAR $1.05
- Resistance Level
- XPON $0.99
- THAR $1.28
- Average True Range (ATR)
- XPON 0.08
- THAR 0.11
- MACD
- XPON 0.03
- THAR 0.03
- Stochastic Oscillator
- XPON 82.32
- THAR 89.33
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.